KRAS and glioblastoma: There is growing evidence that RT-induced K-RAS/ERK signaling activation elevates CD44 expression through downregulation of miR-202 and miR-185 expression, promoting SRC activation to drive cancer stemness and EMT as a pivotal mechanism to mesenchymal transition in GBM cells (61).